Cinacalcet hydrochloride: calcimimetic for the treatment of hyperparathyroidism

References

• Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocrinol. Rel. Calcer. 10, 309–322 (2003).
   PubMed Web of Science ®Google Scholar
• Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366, 575–580 (1993).
   PubMed Web of Science ®Google Scholar
• Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev. Endocrinol. Metab. Disord. 1(4), 307–315 (2000).
   PubMedGoogle Scholar
• Portale AA, Halloran PP, Morris RC Jr. Phisiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J. Clin. Invest. 83, 1494–1499 (1989).
   PubMed Web of Science ®Google Scholar
• Kilav R, Silver J, Naveh-Many T. Parathyroid hormone gene expression in hypophoshatemic rats. J. Clin. Invest. 96, 327–333 (1995).
   PubMed Web of Science ®Google Scholar
• Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and in chronic renal failure rats: the effects of calcium, phosphate and vitamin D. J. Clin. Invest. 96, 1786–1793 (1995).
   PubMed Web of Science ®Google Scholar
• Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J. Clin. Invest. 92, 1436–1443 (1993).
   PubMed Web of Science ®Google Scholar
• Goodman WG, Veldhuis JD, Belin TR et al. Calcium-sensing by parathyroid gland in secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 83, 2765–2772 (1998).
   PubMed Web of Science ®Google Scholar
• Locatelli F, Bommer J, London GM et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol. Dial. Transplant 16, 459–468 (2001).
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342, 1478–1483 (2000).
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Stack AG, Lewin NW et al. Association of elevated serum PO4, CaPO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 12, 2131–2138 (2001).
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen P, Lazarus JM et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208–2218 (2004).
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcome and Practice Pattern Study. Kidney Int. 67, 1179–1187 (2005).
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42(S3), 1–202 (2003).
   PubMed Web of Science ®Google Scholar
• Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 44(S2), S34–S38 (2004).
   PubMed Web of Science ®Google Scholar
• Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol. Dial. Transplant 19(Suppl. 5), v15–v19 (2004).
   Web of Science ®Google Scholar
• Goldsmith D, Ritz E, Covic A. Vascular calcification: a stiff challenge for the nefrologist. Kidney Int. 66, 1315–1333 (2004).
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SM, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary aortic calcification in hemodialysis patients. Kidney Int. 62, 245–252 (2002).
   PubMed Web of Science ®Google Scholar
• Chertow GM, Raggi P, McCarthy JT et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and ateriosclerotic vascular disease in hemodialysis patients. Am. J. Nephrol. 23, 307–314 (2003).
   PubMed Web of Science ®Google Scholar
• Asmus HG, Braun J, Krause R et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol. Dial. Transplant 20, 1653–1661 (2005).
   PubMed Web of Science ®Google Scholar
• Danment SJP, Webster I. The pharmacology of lanthanum carbonate (Fosrenol®): a novel, non-aluminium, non-calcium phosphate binder. Proceedings to 36th annual meeting of the American Society of Nephrology, San Diego, USA. FPO654 (2003).
   Google Scholar
• Hutchinson AJ, Maes B, Vanwalleghem J et al. Efficacy, tolerability and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin. Pract. 100, c8–c19 (2005).
   Google Scholar
• De Broe M, D’Hease P (Lanthanum Study Group). Improving outcomes of hyperphosphataemia. Nephrol. Dial. Transplant 19(Sl1), i14–i18 (2004).
   Google Scholar
• Lacour B, Lucas A, Auchere D et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 67(3), 1062–1069, (2005).
   PubMed Web of Science ®Google Scholar
• Finn WF. No evidence for hepatotoxity after 2 years of lanthanum carbonate therapy. Proceeding of the 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, USA SA-PO950 (2005).
   Google Scholar
• Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63, 1483–1490 (2003).
   PubMed Web of Science ®Google Scholar
• Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J. Am. Soc. Nephrol. 12, 1242–1248 (2001).
   PubMed Web of Science ®Google Scholar
• Foley RN, Li S, Liu J et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J. Am. Soc. Nephrol. 16(1), 210–218 (2005).
   PubMed Web of Science ®Google Scholar
• Kinnaert P, Nagy N, Decoster-Gervy C, de Pauw L, Salmon I, Vereerstraeten P. Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. World J. Surg. 24, 1391–1395 (2000).
   PubMed Web of Science ®Google Scholar
• Weigel RJ. Nonoperative management of hyperparathyroidism: present and future. Curr. Opin. Oncol. 13, 33–38 (2001).
   PubMed Web of Science ®Google Scholar
• Chow CC, Chan WB, Li JK et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroididsm. J. Clin. Endocrinol. Metab. 88, 581–587 (2003).
   PubMed Web of Science ®Google Scholar
• Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 88, 1067–1178 (2003).
   Google Scholar
• Shane E. Parathyroid carcinoma. J. Clin. Endocrinol. Metab. 86(2), 485–493 (2001).
   PubMed Web of Science ®Google Scholar
• Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr. Pharm. Des. 8(23), 2077–2087 (2002).
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308 (2), 627–635 (2004).
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Steffey ME, Fox J. The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism. Pediatr. Nephrol.10(3), 275–279 (1996).
   PubMed Web of Science ®Google Scholar
• Goodman WG, Frazao JM, Goodkin DA et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 58, 436–445 (2000).
   PubMed Web of Science ®Google Scholar
• Goodman WG, Turner SA. Future role of calcimimetics in end-stage renal disease. Adv. Ren. Rep. Ther. 9(3), 200–208 (2002).
   PubMedGoogle Scholar
• Goodman WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone in hemodialysis with secondary hyperparathyroidism. J. Am. Soc. Nephrol. 13, 1017–1024 (2002)
   PubMed Web of Science ®Google Scholar
• Kifor O, Moore FD Jr, Wang P et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81, 1598–1606 (1996).
   PubMed Web of Science ®Google Scholar
• Goodman WG, Veldhuis JD, Belin TR et al. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 83, 2765–2772 (1998).
   PubMed Web of Science ®Google Scholar
• Harris R, Padhi D, Salfi M et al. The impact of hepatic impairment on the pharmacokinetics of cinacalcet HCl. Proc. World Con. Nephrol. (Berlin) M476 (2003).
   Google Scholar
• Padhi D, Harris R, Salfi M et al. Cinacalcet HCl absorption is not affected by coadministration of medications commonly prescribed to chronic kidney disease patients (pantoprazole sodium, sevelamer HCl, and calcium carbonate). Proceedings of 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, SA-P0744 (2003).
   Google Scholar
• Harris RZ, Padhi D, Marbury TC et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am. J. Kidney Dis. 44(6), 1070–1076 (2004).
   PubMed Web of Science ®Google Scholar
• Padhi D, Harris R, Salfi M et al. The pharmacokinetics (PK) of cinacalcet HCl are comparable in patients with chronic kidney disease (CKD) receiving hemodialysis (HD) or chronic ambulatory peritoneal dialysis (CAPD). Proceedings of the 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, SA-P0745 (2003).
   Google Scholar
• Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J. Am. Soc. Nephrol. 14(3), 575–583 (2003).
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 63(1), 248–254 (2003).
   PubMed Web of Science ®Google Scholar
• Goodmann WG, Hladik GA, Turner SA et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. 13, 1017–1024 (2002).
   PubMed Web of Science ®Google Scholar
• Block GA, Coyne DW, Goodman WG et al. The calcimimetic AMG 073: a potential novel therapy for secondary hyperparathyroidism. Proceedings of the Annual Meeting of the American Society of Nephrology, Philadelphia, PA, USA. SU-PO509 (2002).
   Google Scholar
• Cunningham J, Urena P, Reichel H et al. Long term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end-stage renal disease (ESRD). Proceedings of the 42nd Congress of the European Renal Association and the European Dialysis and Transplant Association, Istanbul, Turkey SP210 (2005).
   Google Scholar
• Charytan C, Coburn JW, Chonchol M et al Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis. 46, 58–67. (2005).
   PubMed Web of Science ®Google Scholar
• Chonchol M, Kopyt N, Herman J et al. Cinacalcet HCl reduces parathyroid hormone (PTH) in patients with stage 3 and 4 chronic kidney disease (CKD). Am. J. Kidney Dis. 43, 19A (2004).
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, De Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350(15), 1516–1525 (2004).
   PubMed Web of Science ®Google Scholar
• Moe S, Chertow GM, Coburn JW et al. Achieving NFK-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 67, 760–771 (2005).
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind multicenter study. J. Am. Soc. Nephrol. 16, 800–807 (2005).
   PubMed Web of Science ®Google Scholar
• Goodman WG, Fadda GZ, Filkelstein FO et al. Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism (HPT). Proceedings of the 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, SA-PO741 (2003).
   Google Scholar
• Frazao JM, Holzer H, Stummovol HK et al. Cinacalcet maintains achievement of NKF-K/DOQI™ treatment targets for secondary hyperparathyroidism (HPT) in patients on dialysis. Proceedings of the 42nd Congress of the European Renal Association and the European Dialysis and Transplant Association, Istanbul, Turkey. SP209 (2005).
   Google Scholar
• Cunningham J, Holzer H, Reichel H et al. Sustained, long-term reductions in parathyroid hormone (iPTH) after 3 years of treatment with the calcimimetic cinacalcet HCl in patients with secondary hyperparathyroidism (SHPT). Proc. World Con. Nephrol. (Berlin) M479 (2003).
   Google Scholar
• Moe SM, Goodman WG, Cunningham J et al. Cinacalcet HCl sustains long-term control of secondary hyperparathyroidism (HPT). Proceeding of the 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, USA F-PO755 (2005).
   Google Scholar
• Moe SM, Cunningham J, Brommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetics cinacalcet HCl. Nephrol. Dial. Transplant 20, 2168–2193 (2005).
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 68, 1793–1800 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am. J. Kidney Dis. 29, 496–502 (1997).
   PubMed Web of Science ®Google Scholar
• Coen G, Mazzaferro S, Ballanti P et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic failure: a cross-sectional study. Nephrol. Dial. Transplant 18, 813–819 (1996).
   Google Scholar
• Spasovski GB, Bervoets AR, Behets GJ et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol. Dial. Transplant 18, 1159–1166 (2003).
   PubMed Web of Science ®Google Scholar
• Spiegel DM, Raggi P, Mehta R et al. Coronary and aortic calcifications in patients new to dialysis. Hemodial. Int. 8(3), 265–272 (2004).
   PubMedGoogle Scholar
• Malluche HH, Monier-Faugere MC, Wang G et al. Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). Proceedings of the 41st Congress of the European Renal Association and the European Dialysis and Transplant Association. Lisbon, M016 (2004).
   Google Scholar
• Wada M, Furuya Y, Kobayashi N et al. The calcimimetic compound, cinacalcet HCl, ameliorated osteitis fibrosa in rats with chronic renal insufficiency. J. Bone Miner. Res. 18, s99 (2003).
   Google Scholar
• Ishii H, Wada M, Furuya Y et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26, 175–182 (2000).
   PubMed Web of Science ®Google Scholar
• Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant 20, 1232–1237 (2005).
   PubMed Web of Science ®Google Scholar
• Colloton M, Shatzen E, Miller G et al. Cinacalcet HCL attenuates parathyroid hyperplasia in rat model of secondary hyperparathyroidsm. Kidney Int. 67, 467–476 (2005).
   PubMed Web of Science ®Google Scholar
• Ogata H, Ritz E, Odoni G, Amann K, Orth SR. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J. Am. Soc. Nephrol. 14(4), 959–967 (2003).
   PubMed Web of Science ®Google Scholar
• Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol. Dial. Transplant 20, 1311–1314 (2005).
   PubMed Web of Science ®Google Scholar
• Serra AL, Schwarz AA, Wick FH et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol. Dial. Transplant 20, 1315–1319 (2005).
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, Faiman C, Bilezikian JP et al. The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary hyperparathyroidism after parathyroidectomy. Proceedings of the 26th Annual Meeting of The American Society for Bone and Mineral Research. SA-420 (2003).
   Google Scholar
• Peacock M, Bilezikian JP, Klassen PS et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90(1), 135–141 (2005).
   PubMed Web of Science ®Google Scholar
• Rothe HM, Shapiro WB, Malaton A, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly influences the severity of secondary hyperparathyroidism (sHPT) in hemodialysis patients. Proceedings of the 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, USA SA-PO895 (2005).
   Google Scholar
• Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly influences the response to a single dose of Cinacalcet HCl. Proceedings of the 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, USA F-FC128 (2005).
   Google Scholar
• David DS, Sakai S, Brennan BL et al. Hypercalcemia after renal transplantation. Long term follow-up data. N. Engl. J. Med. 289, 398–401 (1973).
   PubMed Web of Science ®Google Scholar
• Wada M, Furuya Y, Sakiyama J et al. The calcimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. 100, 2977–2983 (1997).
   PubMed Web of Science ®Google Scholar
• Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 66, 2293–2299 (2004).
   PubMed Web of Science ®Google Scholar
• Henley C, Colloton M, Cattley RC et al. 1,25-dihydroxyvitamin D3 but not Cinacalcet HCl (Sensipar®/Mimpara®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol. Dial. Transplant 20(7), 1370–1377 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Mendoza FC, Aguilera-Tejero E et al. Calcimimetic NPS R-568 decreases vascular calcification in uremic rats treated with calcitriol. Proceedings of the Annual Meeting of the American Society of Nephrology, St. Luis, Missouri F-PO983 (2004).
   Google Scholar
• Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol. Metab. 10, 66–71 (1999).
   Google Scholar